New MRI dye aims to sharply detect dangerous prostate tumors
NCT ID NCT06262139
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 23 times
Summary
This early-stage study tests a new MRI contrast agent called MT218 in 12 men with aggressive prostate cancer (Gleason score 8-10) who are scheduled for surgery. The goal is to see if this dye can better highlight dangerous tumors compared to standard MRI and PSMA-PET/CT scans. Participants will receive the dye before a research MRI, and results will be checked against their surgical tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MRI SCAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.